Invuity’s patented Intelligent Photonics® devices provide direct visualization of the surgical cavity enabling enhanced precision, efficiency and safety. Our technology is integrated into sophisticated retractor systems, handheld devices and intracavity drop-in illuminators; each utilizing our proprietary waveguide technology that directs and shapes light into broad, uniform illumination to provide enhanced direct visualization inside dark surgical cavities. In addition, it converts traditional thermally hot, concentrated light output to thermally cool volumetric illumination throughout the entire surgical cavity.
Transforming Minimal access Surgeries Through Advanced Visualization
Invuity is committed to leveraging advanced photonics technology to transform and create a new standard of care for minimal access surgery.
SAN FRANCISCO, March 15, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY) (“Invuity” or the “Company”), a leading medical technology company focused on minimal access surgery, today announced the pricing of its public offering of 6,200,000 shares of its common stock at a price to the public of $3.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of its common stock. William Blair & Company, L.L.C. is acting as the sole book-running manager for the offering. The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-212395) that was initially filed with the U.S...Read More
SAN FRANCISCO, March 14, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY) ("Invuity" or the "Company"), a leading medical technology company focused on minimal access surgery, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Invuity expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. Invuity intends to use the net proceeds from the offering for continued expansion of its sales and marketing activities, working capital and other general corporate purposes. William Blair & Company, L.L.C. is acting as the sole book-running manager...Read More
Scott D. Flora appointed Interim President and Chief Executive Officer Philip Sawyer steps down as President and Chief Executive Officer SAN FRANCISCO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announced that Scott D. Flora, a member of the Company’s Board of Directors since 2017, has been appointed to serve as Interim President and Chief Executive Officer. This appointment follows Philip Sawyer’s resignation as President, Chief Executive Officer and a member of the Company’s Board of Directors. Gregory T. Lucier, Chairman of the Invuity Board of Directors said, “Phil is a truly vis...Read More
The dynamic fluorescence imaging of the PhotonVue allows me to confidently offer more advanced nipple sparing mastectomy techniques and single stage procedures to a broader patient population. Specifically, confirming tissue perfusion during the reconstruction enables me to discuss these techniques with patients who are smokers, diabetics, those who were previously radiated or have high BMIs.
Director of Bucks County Aesthetic Center – Bensalem, PA
“The illumination of the operative field creating improved operative efficiency (with no longer needing to wear my headlight) along with added patient safety have made the Eikon Illuminated Retractor System the tool of choice in my skin sparing and nipple sparing mastectomies.”
“Invuity’s technology enables me to perform advanced breast procedures with remarkable visualization. This is truly an enabling technology that will be greatly appreciated by dedicated breast surgeons and plastic surgeons.”
Mission Viejo, CA